Printer Friendly

Printed from http://www.researchandmarkets.com/reports/1524678

Primary Immune Deficiency (PID) - Pipeline Review, Q1 2011

Description:
Primary Immune Deficiency (PID) - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Primary Immune Deficiency (PID) - Pipeline Review, Q1 2011', provides an overview of the Primary Immune Deficiency therapeutic pipeline. This report provides information on the therapeutic development for Primary Immune Deficiency, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Primary Immune Deficiency. 'Primary Immune Deficiency - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- A snapshot of the global therapeutic scenario for Primary Immune Deficiency.
- A review of the Primary Immune Deficiency products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Primary Immune Deficiency pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Primary Immune Deficiency.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Primary Immune Deficiency pipeline depth and focus of Primary Immune Deficiency therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
 
Contents:


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Primary Immune Deficiency (PID) Overview
Therapeutics Development
An Overview of Pipeline Products for Primary Immune Deficiency (PID)
Primary Immune Deficiency (PID) Therapeutics under Development by Companies
Primary Immune Deficiency (PID) Therapeutics under Investigation by Universities/Institutes
Companies Involved in Primary Immune Deficiency (PID) Therapeutics Development
Omrix Biopharmaceuticals, Inc.
Talecris Biotherapeutics Holdings Corp
CSL Limited
Universities/Institutes Involved in Primary Immune Deficiency (PID) Therapeutics Development
Primary Immune Deficiency (PID) Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
IgG with Proline (IgPro) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Immune globulin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Omr-IgG-am - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
Busulfan + Cyclophosphamide + Antithymocyte Globulin + Allogeneic Stem Cell Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cyclophosphamide + Allogeneic stem cell transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Primary Immune Deficiency (PID) - Featured News
Sep 24, 2010: Update Of Product Withdrawal/Product Recall Octopharm's Octagam 10% (octagam 100mg/ml)
Sep 24, 2009: Octapharma submits BLA To US FDA For Octagam 10%
Jul 15, 2009: Baxter And Halozyme Announces Completion Of Patient Enrollment In Phase III Pivotal Trial Of GAMMAGARD LIQUID(TM) With rHuPH20 Enzyme.
Mar 16, 2009: Data Presented at AAAAI Reinforce Baxter's Commitment to Making GAMMAGARD LIQUID Therapy More Convenient
Jan 05, 2009: Phase III Trial Begins For GAMMAGARD LIQUID Plus rHuPH20 In Primary Immunodeficiency Patients.
Mar 16, 2008: Baxter Presents Latest Clinical Trial Results Of GAMMAGARD LIQUID Administered Subcutaneously .
Sep 10, 2007: Baxter and Halozyme Announce Collaboration For Development Of Subcutaneous Gammagard LIQUID Administration using Enhanze Technology
Aug 22, 2007: Baxter to Launch GARDianT, a Groundbreaking Initiative that Helps Provide Continued Access to GAMMAGARD for Current Patients
Sep 26, 2005: Baxter Launches GAMMAGARD LIQUID 10% for Patients With Primary Immunodeficiency Disorders.
May 02, 2005: FDA Approves Baxter's GAMMAGARD Liquid 10% For Patients With Primary Immunodeficiency Disorders.
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Primary Immune Deficiency (PID), 2011
Products under Development for Primary Immune Deficiency (PID) – Comparative Analysis, 2011
Omrix Biopharmaceuticals, Inc., 2011
Talecris Biotherapeutics Holdings Corp, 2011
CSL Limited, 2011
Assessment by Monotherapy Products, 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011

List of Figures
Number of Products under Development for Primary Immune Deficiency (PID), 2011
Products under Development for Primary Immune Deficiency (PID) – Comparative Analysis, 2011
Products under Development by Companies, 2011
Products under Investigation by Universities/Institutes, 2011
Assessment by Monotherapy Products, 2011
Assessment by Combination Products, 2011
Assessment by Route of Administration, 2011
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011
Assessment by Stage and Molecule Type, 2011
 
Ordering:
Order Online - visit http://www.researchandmarkets.com/reports/1524678

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Page 1 of 2
Printed Apr 21th 2014
7:21:56 AM

Fax order form

To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net

Order information

Please verify that the product information is correct and select the format you require.

Product name

Primary Immune Deficiency (PID) - Pipeline Review, Q1 2011

Web Address

http://www.researchandmarkets.com/reports/1524678

Office Code

OC8DINPNQQNUVR

 

Report Formats

Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User EUR 368
Electronic (PDF) - Site License EUR 735
Electronic (PDF) - Enterprisewide EUR 1103

Contact information

Please enter all the information below in block capitals.

Title:
Mr Mrs Dr Miss Ms Prof
First Name:
Last Name:
Email Address:
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2
Printed Apr 21th 2014
7:21:56 AM

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

American Express

Diners Club

Master Card

Visa

Cardholder's Name:
Cardholder's Signature:
Expiry Date:
/
Card Number:
CVV Security Code:
Issue date:
/ (Diners Club only)
 
Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Pay by Wire Transfer:

Please transfer funds to:

Account Number:
83313083
Sort Code:
98-53-30
Swift Code:
ULSBIE2D
IBAN Number:
IE78ULSB98533083313083
Bank Address:
Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
 

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)